Companies ›Healthcare ›NSPR

NSPR — Nasdaq Diversified Medical Equipment & Supplies

InspireMD, Inc.

$0,90

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

75,4M USD

P/E

—

EV / Rev

3,8x

Div yield

—

Op margin

-552,6 %

ROE

-111,9 %

Net margin

-543,3 %

Debt / equity

—

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

$0,67

Open

—

Next earnings

2026-08-03

Ex-dividend

—

TR 1Y

—

About

InspireMD, Inc. is classified under Energy / Oil & Gas Exploration & Production and appears not currently profitable on the latest normalized snapshot.

Business. InspireMD, Inc. is classified under Energy / Oil & Gas Exploration & Production and appears not currently profitable on the latest normalized snapshot.

Classification99 %

SectorHealth Care

Industry groupDiversified Medical Equipment & Supplies

Generated · rules-based

Sell-side consensus

BUY2 analysts

2 buy0 hold0 sell

Avg 12m price target5,00

Analyst recommendations

2 analysts · consensus Buy

Buy2

Hold0

Sell0

12-month price target

5,00

Consensus of sell-side coverage.

Upcoming events

EarningsQ2 2026 earnings (expected)2026-08-03 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

2 analysts · indicative

Ownership→

Northern Trust Investments, Inc.

largest disclosed fund holder

Profitability→

-111,9 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning NSPR.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,7 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Energy+0,6 %+3,3 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Information Technology+0,2 %+7,9 %−0,4 %

Financials−0,3 %−3,0 %−1,0 %

Consumer Staples−0,7 %+2,5 %−1,3 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,8 %−1,6 %−2,4 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to NSPR. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-01 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ2 2026 earnings (expected)2026-08-03 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

InspireMD, Inc. is classified under Energy / Oil & Gas Exploration & Production and appears not currently profitable on the latest normalized snapshot.

Classification99 %

SectorHealth Care

Industry groupDiversified Medical Equipment & Supplies

AI synthesis

GENERATED

InspireMD, Inc. (NSPR) is currently classified as Exploration & Production within Oil & Gas Exploration & Production (Energy). Classification confidence: 0.92 (rule-based classification). Capital structure on the latest snapshot: total assets 56,471,000 USD, total equity 43,617,000, short-term debt 0, long-term debt 0. Net cash position is approximately 41,570,000 USD. Self-calculated market cap is 75,421,655 USD (market_price × shares_outstanding_diluted). Profitability profile: revenue 3,398,000, gross profit 687,000, operating income -13,978,000, net income -13,689,000. Return on equity ~-111.9%. Return on assets ~-86.4%. Operating-cash-flow to net-income ratio is 0.72. Risk profile from automated assessment: liquidity risk high, dilution risk high. Flags: Diluted share count is materially above the basic share count.; Filings reference going-concern or substantial-doubt language.; Source documents mention dilution or offering risk.. Recent news context: [TRIGGER] allocator_boost: allocator_boost (allocator) on NSPR — watcher=allocator; producer_version=ws49-p2a-v2; plan_date=2026-08-01; rank=21; ev=8.200615; company_id=629e8f8b-b4cc-477b-a8d5-50b1e7ae68bd; term_contributions={'event_proximity': 2.01096, 'gradability': 2.0, 'staleness': 4.189655, 'credibility_interest': 0.0}; days_since_analysis=65; pending_promises=0; reason=Allocator coverage boost rank #21 EV=8.200615 for NSPR (hot+stale; days_since=65); calendar_week={'next_event_date': '2026-08-03', 'days_until': 2, 'bases': ['expected (estimated date)'], 'in_plan_rows': True, 'never_analyzed': False}; contributing_watchers=allocator (source=allocator; url=allocator:2026-08-01:NSPR). Additional context: allocator_boost: watcher=allocator; producer_version=ws49-p2a-v2; plan_date=2026-08-01; rank=21; ev=8.200615; company_id=629e8f8b-b4cc-477b-a8d5-50b1e7ae68bd; term_contributions={'event_proximity': 2.01096, 'gradability': 2.0, 'staleness': 4.189655, 'credibility_interest': 0.0}; days_since_analysis=65; pending_promises=0; reason=Allocator coverage boost rank #21 EV=8.200615 for NSPR (hot+stale; days_since=65); calendar_week={'next_event_date': '2026-08-03', 'days_until': 2, 'bases': ['expected (estimated date)'], 'in_plan_rows': True, 'never_analyzed': False}; contributing_watchers=allocator.

Key takeaways

Return on equity is about -111.9%.
Debt to equity is about 0.0x.
[TRIGGER] allocator_boost: allocator_boost (allocator) on NSPR — watcher=allocator; producer_version=ws49-p2a-v2; plan_date=2026-08-01; rank=21; ev=8.200615; company_id=629e8f8b-b4cc-477b-a8d5-50b1e7ae68bd; term_contributions={'event_proximity': 2.01096, 'gradability': 2.0, 'staleness': 4.189655, 'credibility_interest': 0.0}; days_since_analysis=65; pending_promises=0; reason=Allocator coverage boost rank #21 EV=8.200615 for NSPR (hot+stale; days_since=65); calendar_week={'next_event_date': '2026-08-03', 'days_until': 2, 'bases': ['expected (estimated date)'], 'in_plan_rows': True, 'never_analyzed': False}; contributing_watchers=allocator (source=allocator; url=allocator:2026-08-01:NSPR)
dollars in thousands, except share and per share data) March 31 December 31 2026 2025 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 11,362 $ 8,939 Marketable securities 30,208 45,272 Accounts receivable: Trade, net 2,381 2,168 Other 407 400 Prepaid expenses 1,200 1,296 Inventory 3,036 3,396 TOTAL CURRENT ASSETS 48,594 61,471 NON-CURRENT ASSETS: Long term deposit 446 442 Property, plant and equipment, net 3,651 3,584 Operating lease right of use assets 2,595 2,758 Fund in respect of employee rights upon retirement 1,185 1,149 TOTAL NON-CURRENT ASSETS 7,877 7,933 TOTAL ASSETS $ 56,471 $ 69,404 F- 2 INSPIREMD, INC.
dollars in thousands, except share data) Shares Amount Shares Amount capital deficit equity Common stock Preferred C shares Additional paid-in Accumulated Total Shares Amount Shares Amount capital deficit equity BALANCE AT January 1, 2025 26,611,033 3 1,718 - * 289,589 ( 253,506 ) 36,086 Net loss ( 11,166 ) ( 11,166 ) Exercise of pre-funded warrants 643,860 - * - - - - - * Issuance of common stock, included at the market offering net of $ 22 issuance costs 273,621 - * - - 696 - 696 Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of 29,295 shares 2,224,147 - * - - 2,729 - 2,729 BALANCE AT March 31, 2025 29,752,661 3 1,718 - * 293,014 ( 264,672 ) 28,345 * Represents an amount less than $1 thousand The accompanying notes are an integral part of the condensed consolidated financial statements.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Quarterly

Annual

QUARTERLYFiled 2026-03-31

Q4 2025 · Quarter highlights

Open report →

Revenue $3.4M; Operating income -$14.0M.

Revenue$3.4M

Operating income-$14.0M

Net income-$13.7M

Free cash flow-$12.5M

EPS—

Operating cash flow-$12.3M

Financials

Income statement

Revenue$3.4M

Gross profit$687.0k

Operating income-$14.0M

Net income-$13.7M

Margins

Gross margin20.2%

Operating margin-411.4%

Net margin-402.9%

FCF margin-368.8%

Balance sheet

Total assets$56.5M

Total liabilities$12.9M

Total equity$43.6M

Cash & equivalents$11.4M

Long-term debt—

Cash flow

Operating cash flow-$12.3M

CapEx$194.0k

Free cash flow-$12.5M

SBC$2.1M

P&L flow · revenue → net income

Highlights

▍Revenue $3.4M
▍Operating income -$14.0M
▍Net margin -402.9%

Valuation FY

Market price

$0,90

Market cap

$75.4M

Enterprise valueⓘ

$33.9M

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

3.8x

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

1.7x

P / Tangible bookⓘ

1.7x

Tangible book

$43.6M

Net cashⓘ

$41.6M

Current ratioⓘ

5.2

Debt / equityⓘ

—

ROAⓘ

-86.4%

ROEⓘ

-1.1%

Cash conversionⓘ

72.0%

CapEx / revenueⓘ

18.5%

SBC / revenueⓘ

1.4%

Dilution ratioⓘ

78.9%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

Peer comparison8 peers · vs NSPR · multiples and returns

ABT—

Abbott Laboratories

$106,04

185,3B USD

P/E

26,3x

— vs self

Div yield

2,4 %

— vs self

ROE

12,5 %

+124,4 vs self

MDT—

Medtronic PLC

$85,36

109,3B USD

P/E

21,4x

— vs self

Div yield

3,4 %

— vs self

ROE

9,7 %

+121,6 vs self

MDLN—

MEDLINE INC.

$39,42

51,8B USD

P/E

202,6x

— vs self

Div yield

—

— vs self

ROE

—

— vs self

SYK—

Stryker Corp

$319,04

123,2B USD

P/E

38,0x

— vs self

Div yield

—

— vs self

ROE

13,5 %

+125,4 vs self

BDX—

Becton Dickinson And Co

$165,62

47,1B USD

P/E

25,6x

— vs self

Div yield

2,8 %

— vs self

ROE

7,0 %

+118,8 vs self

HSIC—

Henry Schein Inc

$88,21

10,1B USD

P/E

80,5x

— vs self

Div yield

—

— vs self

ROE

3,0 %

+114,8 vs self

BAX—

Baxter International Inc

$22,77

11,8B USD

P/E

—

— vs self

Div yield

2,3 %

— vs self

ROE

-15,4 %

+96,4 vs self

SOLV—

SOLVENTUM CORPORATION

$76,83

13,3B USD

P/E

8,6x

— vs self

Div yield

—

— vs self

ROE

30,8 %

+142,7 vs self

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

-0,73

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-05-16 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	-0,74
Revenue	—no estimate	—no estimate	10,4M USD
Operating income	—no estimate	—no estimate	-64,2M USD

Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-01

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution3 analysts

Strong buy0

Buy3

Hold0

Sell0

Strong sell0

12-month price target$3,67 · Median $4,00

Low $3,00High $4,00

Operating income · consensus-64,2M USD

EPS surprise

−2,7 %

reported vs consensus · miss

Revenue surprise

−13,5 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$4,00

Mean$5,00

Median$5,00

High$6,00

Spot$0,90

+455.6 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskHigh

Liquidity riskHigh

Filing-based flags

Diluted share count is materially above the basic share count.
Filings reference going-concern or substantial-doubt language.
Source documents mention dilution or offering risk.

Benchmarks vs cohort

Op Margin-552,6 %Bottom quartile

Net Margin-543,3 %Bottom quartile

ROE-111,9 %Bottom quartile

Capex / Rev18,5 %Best in class

D/E0,00Above median

Cash Conv0,72Below median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net acquired 26 276 sh1 grants1 insiders

Arnold KathrynDirector · Options to purchase common stock (right to buy) → Common StockAcquired 26 276 @ $1,89grant · 2025-12-30

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Regulatory filings
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data
Reference data

How metrics are computed

Cash Conversion Ratio
operating_cash_flow / net_income
Market Price
input from market-data provider (delayed close or quote-shim mid)
Ev To Revenue
enterprise_value / revenue
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Return On Equity
net_income / total_equity
Market Cap
market_price * shares_outstanding_diluted

Source documents

InspireMD, Inc. company facts · 2026-08-01
InspireMD, Inc. 10-Q 2026-05-07 · 2026-08-01
InspireMD, Inc. 10-K 2026-03-18 · 2026-08-01
InspireMD, Inc. 10-Q 2025-11-10 · 2026-08-01
InspireMD, Inc. 10-Q 2025-08-04 · 2026-08-01
allocator_boost (allocator) on NSPR · 2026-08-01
InspireMD Inc Market data — analyst estimates · 2026-08-01
InspireMD, Inc. HA canonical relationships · 2026-08-01

Ownership & reference

Top holders

Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M

Leadership

Marvin L. SlosmanPresident, Chief Executive Officer, Director

Insider activity

Net buying15 buys · 12 sellsnet $298K11 insiders · last 365d

Stuka PaulDirector · Common StockBought 20 000 @ $0,88$18K · 2026-05-27
Gleason Shane ThomasChief Commercial Officer · Common StockSold 22 778 @ $1,01$23K · 2026-05-19
Stuka PaulDirector · Common StockBought 5 000 @ $1,15$6K · 2026-05-14
Stuka PaulDirector · Common StockBought 10 000 @ $1,16$12K · 2026-05-13
Slosman MarvinDirector, CEO and President · Common StockBought 21 000 @ $1,20$25K · 2026-05-12
Stuka PaulDirector · Common StockBought 10 000 @ $1,19$12K · 2026-05-11
Stuka PaulDirector · Common StockBought 65 626 @ $1,16$76K · 2026-05-08
Ward Scott R.Director · Common StockBought 73 255 @ $1,15$84K · 2026-05-07
Stuka PaulDirector · Common StockBought 6 378 @ $1,15$7K · 2026-05-07
ROUBIN GARY SDirector · Common StockBought 90 000 @ $1,18$106K · 2026-05-07
Ward Scott R.Director · Common StockBought 15 995 @ $1,15$18K · 2026-05-06
Stuka PaulDirector · Common StockBought 1 517 @ $1,12$2K · 2026-05-06
Gleason Shane ThomasChief Commercial Officer · Common StockSold 2 941 @ $1,59$5K · 2026-02-02
Gleason Shane ThomasChief Commercial Officer · Common StockSold 2 000 @ $1,60$3K · 2026-02-02
Gleason Shane ThomasChief Commercial Officer · Common StockSold 2 900 @ $1,63$5K · 2026-01-30
Gleason Shane ThomasChief Commercial Officer · Common StockSold 5 000 @ $1,65$8K · 2026-01-29
Gleason Shane ThomasChief Commercial Officer · Common StockSold 12 395 @ $1,65$20K · 2026-01-28
Gleason Shane ThomasChief Commercial Officer · Common StockSold 4 781 @ $1,66$8K · 2026-01-27
Gleason Shane ThomasChief Commercial Officer · Common StockSold 8 411 @ $1,57$13K · 2026-01-22
Gleason Shane ThomasChief Commercial Officer · Common StockSold 17 593 @ $1,62$29K · 2026-01-21
Gleason Shane ThomasChief Commercial Officer · Common StockSold 2 955 @ $1,59$5K · 2026-01-20
Gleason Shane ThomasChief Commercial Officer · Common StockSold 2 250 @ $1,61$4K · 2026-01-16
Gleason Shane ThomasChief Commercial Officer · Common StockSold 2 909 @ $1,58$5K · 2026-01-15
Ward Scott R.Director · Common StockOther 88 053 · 2026-01-14
Tommasoli AndreaChief Operating Officer · Common StockOther 226 695 · 2026-01-14

Short positioning

76.9Kshares short+3.2% vs prior

1days to cover

19.0%short of daily vol

50.2Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

NSPRCanonical

Nasdaq · USD

Intel & risk

PredictorBeat prob45 %Surprise+0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskHigh

Liquidity riskHigh

Diluted share count is materially above the basic share count.

Filings reference going-concern or substantial-doubt language.

Source documents mention dilution or offering risk.

Evidence & claims

From filings & derived data

Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 32.5%Derived (calculated)
Capex (YoY) (2025-12-31 vs 2024-12-31): 18.5%Derived (calculated)
Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 15.0%Derived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 0.0%Derived (calculated)
EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 0.0%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): 48.3%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 53.0%Derived (calculated)
Revenue (YoY) (2025-12-31 vs 2024-12-31): 28.1%Derived (calculated)
R&D expense (YoY) (2025-12-31 vs 2024-12-31): 10.0%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): -48.1%Derived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -60.5%Derived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -52.7%Derived (calculated)
Gross profit (YoY) (2025-12-31 vs 2024-12-31): 75.9%Derived (calculated)
Net margin (FY 2025-12-31): -543.4%Derived (calculated)
Gross margin (FY 2025-12-31): 29.5%Derived (calculated)
Return on equity (FY 2025-12-31): -88.4%Derived (calculated)
Return on assets (FY 2025-12-31): -70.3%Derived (calculated)
Current ratio (FY 2025-12-31): 5.74xDerived (calculated)
Debt-to-equity (FY 2025-12-31): 0.26xDerived (calculated)
Net income (YoY) (2025-12-31 vs 2024-12-31): -52.4%Derived (calculated)
Net income (annual): USD -48.79MSEC XBRL filing
Total operating expenses (annual): USD 52.26MSEC XBRL filing
Pre-tax income (annual): USD -48.72MSEC XBRL filing
Shares outstanding (annual): 43.53MSEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-08-03 00:00 UTCTRANSCRIPTUpcomingEarnings call — Q3 2026

2026-08-03EVENTUpcomingQ2 2026 earnings (expected) estimated date

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated

2026-06-11FILING8-K filing →

2026-06-03FILING8-K filing →

2026-05-27 00:00 UTCINSIDER12 insider transactions — 2026-05 · net buy $343k

2026-05-27INSIDERStuka Paul bought 20.0k sh — Director ~$18k

2026-05-22FILING8-K filing →

2026-05-19INSIDERGleason Shane Thomas sold 22.8k sh — Chief Commercial Officer ~$23k

2026-05-14INSIDERStuka Paul bought 5.0k sh — Director ~$6k

2026-05-13INSIDERStuka Paul bought 10.0k sh — Director ~$12k

2026-05-12INSIDERSlosman Marvin bought 21.0k sh — Director, CEO and President ~$25k

2026-05-11INSIDERStuka Paul bought 10.0k sh — Director ~$12k

2026-05-08INSIDERStuka Paul bought 65.6k sh — Director ~$76k

2026-05-07FILING10-Q filing →

2026-05-07INSIDERWard Scott R. bought 73.3k sh — Director ~$84k

2026-05-07INSIDERStuka Paul bought 6.4k sh — Director ~$7k

2026-05-07INSIDERROUBIN GARY S bought 90.0k sh — Director ~$106k

2026-05-06INSIDERWard Scott R. bought 16.0k sh — Director ~$18k

2026-05-06INSIDERStuka Paul bought 1.5k sh — Director ~$2k

2026-05-04FILING8-K filing →

2026-05-01FILING8-K filing →

2026-04-20FILINGDEF 14A filing →

2026-04-03FILING8-K filing →

2026-04-03FILING424B5 filing →

2026-03-18FILING10-K filing →

2026-03-18FILING8-K filing →

2026-03-04FILING8-K filing →

2026-02-02 00:00 UTCINSIDER2 insider transactions — 2026-02

2026-02-02INSIDERGleason Shane Thomas sold 2.9k sh — Chief Commercial Officer ~$5k

2026-02-02INSIDERGleason Shane Thomas sold 2.0k sh — Chief Commercial Officer ~$3k

2026-01-30 00:00 UTCINSIDER19 insider transactions — 2026-01

2026-01-30INSIDERGleason Shane Thomas sold 2.9k sh — Chief Commercial Officer ~$5k

2026-01-29INSIDERGleason Shane Thomas sold 5.0k sh — Chief Commercial Officer ~$8k

2026-01-28INSIDERGleason Shane Thomas sold 12.4k sh — Chief Commercial Officer ~$20k

2026-01-27INSIDERGleason Shane Thomas sold 4.8k sh — Chief Commercial Officer ~$8k

2026-01-22INSIDERGleason Shane Thomas sold 8.4k sh — Chief Commercial Officer ~$13k

Showing the 40 most recent of 52 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-01 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Leadership

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread